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RESUMO 
 
Os carcinomas de células escamosas orais (CCEO) constituem um dos seis tumores 
malignos mais comuns no mundo. A quimioterapia utilizada como terapia 
neoadjuvante e adjuvante à radioterapia ou cirurgia tem mostrado benefícios 
modestos na sobrevida relacionada ao tratamento de CCEO em estágio avançado 
quando comparada à sua utilização no tratamento de outras formas de câncer. O 
Fator Neurotrófico Derivado do Cérebro (BDNF) é um fator de crescimento membro 
da família de neurotrofinas que foi primeiramente conhecido como responsável por 
sustentar o crescimento, a função e a plasticidade das células neurais. O BDNF 
exerce os seus efeitos ligando-se ao receptor de tirosina quinase B (TrkB). Foi 
relatado que o eixo BDNF / TrkB está superexpresso e associado a um mau 
prognóstico, crescimento tumoral, invasão e metástase; transição epitelial-
mesenquimal (EMT) e resistência à quimioterapia em diferentes malignidades 
neurais e não neurais humanas. Os objetivos do presente estudo são revisar a 
literatura sobre o papel da via BDNF / TrkB em CCEO e tumores glandulares e além 
disto, avaliar a expressão de BDNF, seu receptor  (TrkB) e dois alvos dessa via, Akt 
e proteína ribossômica S6 (RPS6), em mucosa oral normal (MON), leucoplasia oral 
(LO) e carcinoma de células escamosas oral (CCEO), e correlacionar essa 
expressão com os desfechos dos pacientes com CCEO, senescência celular e perfil 
tronco. Dez casos de MON, 33 LO e 72 CCEO primários foram incluídos. Os casos 
de CCEO foram montados em microarranjos teciduais (TMAs). Análises imuno-
histoquímicas para BDNF, TrkB, p-TrkB, p-Akt e p-RPS6 foram realizadas em todos 
os casos. A senescência celular e o perfil de células tronco do CCEO foram 
avaliados através da expressão imuno-histoquímica do p16 e BMI-1, 
respectivamente. As lâminas foram digitalizadas em imagens de alta resolução e a 
expressão imuno-histoquímica foi quantificada por meio de análise digital. Os valores 
de corte foram determinados para avaliar a associação de cada marcador com 
características clínico-patológicas. CCEO apresentou expressão aumentada da via 
BDNF / TrkB / Akt em relação ao MON e LO. O CCEO diagnosticado em estágios 
clínicos avançados apresentou uma regulação positiva do BDNF e de p-TrkB. Além 
disso, a superexpressão de BDNF e p-Akt foi identificada como preditora de 
sobrevida pobre, com razões de risco de 2,83 e 2,19, respectivamente. O aumento 
no perfil de células tronco foi correlacionado com uma diminuição na expressão de p-
  
TrkB e p-Akt. Em conjunto, esses dados sugerem que a via BDNF / TrkB / Akt está 
envolvida na aquisição do fenótipo maligno durante a carcinogênese oral e influência 
o prognóstico do CCEO. Pacientes com aumento da expressão dessas proteínas 
foram mais propensos a experimentar menor tempo de sobrevida. Este estudo 
confirma que o BDNF / TrkB é um alvo terapêutico atraente para o carcinoma 
espinocelular oral e em relação aos tumores de glândulas salivares, estudos 
demonstraram que a via BDNF / TrkB está significativamente associada à invasão 
perineural, migração, indução de transição epitelial-mesenquimal e metástase. 
Sendo assim um possível alvo de interesse. 
 
Palavras-chave: câncer bucal, BDNF,TrkB, Akt 
  
ABSTRACT 
 
Oral Squamous Cell Carcinomas (OSCC) are one of the six most common 
malignancies in the world. Chemotherapy used as neoadjuvant therapy and 
adjuvant to radiotherapy or surgery has shown modest survival benefits related to 
the treatment of advanced HNSCC when compared to its use in the treatment of 
other forms of cancer. Brain-derived neurotrophic factor (BDNF) is a growth factor 
member of the neurotrophin family that was first known to be responsible for 
sustaining the growth, function, and plasticity of neural cells. BDNF exerts its effects 
by binding to the receptor of tyrosine kinase B (TrkB). It has been reported that the 
BDNF / TrkB axis is overexpressed and associated with poor prognosis, tumor 
growth, invasion and metastasis; epithelial-mesenchymal transition (EMT) and 
resistance to chemotherapy in different human neural and non-neural malignancies. 
The aim of the present study was to review the literature on the role of the BDNF / 
TrkB signaling pathway in OSCC and glandular tumors and in addition to evaluate 
the expression of BDNF, its  receptor (TrkB) and two targets of this pathway, Akt 
and ribosomal protein S6 (RPS6 ), in normal oral mucosa (NOM), oral leukoplakia 
(OL) and oral squamous cell carcinoma (OSCC), and to correlate this expression 
with the clinical outcomes of the patients with OSCC, cell senescence and stem cell 
profile. Ten cases of NOM, 24 OL and 72 primary OSCC were included. The OSCC 
cases were assembled in tissue microarrays (TMAs). Immunohistochemical 
analyses for BDNF, TrkB, p-TrkB, p-Akt and p-RPS6 were performed in all cases. 
Cell senescence and OSCC stem cell profile were assessed by 
immunohistochemical expression of p16 and BMI-1, respectively. The slides were 
scanned in high resolution images and the immunohistochemical expression was 
quantified by means of digital analysis. Cut-off values were determined to evaluate 
the association of each marker with clinical-pathological characteristics. OSCC 
showed increased expression of the BDNF / TrkB / Akt pathway relative to NOM 
and OL. The OSCC diagnosed in advanced clinical stages presented a positive 
regulation of BDNF and p-TrkB. In addition, overexpression of BDNF and p-Akt was 
identified as a predictor of poor survival, with risk ratios of 2.83 and 2.19, 
respectively. The increase in the stem cell profile was correlated to a decrease in 
the expression of p-TrkB and p-Akt. Together, these data suggest that the BDNF / 
TrkB / Akt signaling pathway is involved in the acquisition of the malignant 
  
phenotype during oral carcinogenesis and influences the prognosis of OSCC. 
Patients with increased expression of these proteins were more likely to experience 
shorter survival times. This study confirms that BDNF / TrkB is an attractive 
therapeutic target for oral squamous cell carcinomas and concerning salivary gland 
tumors, studies have demonstrated that the BDNF / TrkB pathway is significantly 
associated with perineural invasion, migration, induction of epithelial-mesenchymal 
transition, and metastasis. Thus being a possible target of interest. 
 
Keywords: oral squamous cell carcinoma, BDNF, TrkB, Akt 
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1 INTRODUÇÃO 
 
 
O câncer de cabeça e pescoço pode desenvolver-se em diversas 
regiões anatômicas como faringe, hipofaringe, laringe, tonsilas palatinas, cavidades 
nasais e seios paranasais, glândulas como as parótidas e cavidade oral (Marur et 
al. 2016). O câncer oral (CO) representa um importante problema de saúde com 
cerca de 354.860 casos novos estimados no mundo em 2018 (Globocan, 2018). 
Segundo a Agência Internacional de Pesquisa em Câncer (IARC-França), o CO 
abrange as regiões dos lábios, língua (porção móvel), gengivas, mucosa jugal, 
palato, soalho bucal, algumas glândulas salivares. A incidência é maior em homens 
do que em mulheres e afeta na maior parte dos casos indivíduos com faixa etária 
entre cinquenta e sessenta anos de idade (Le Campion et al. 2016; Siegel et al. 
2017). Índia, seguida pela China, Estados Unidos da América, Paquistão e 
Bangladesh mostram a maior incidência de CO no mundo. O Brasil se encontra na 
sexta posição. Tratando-se de continentes, a Ásia abriga as maiores incidências de 
CO em ambos os sexos, seguida pela Europa e América (América Latina, Caribe e 
América do Norte) (IARC). No Brasil, o Instituto Nacional de Câncer José Alencar 
Gomes da Silva (INCA) estimou para o ano de 2018 (biênio 2018–2019), 11.200 
novos casos de CO em homens e 3.500 em mulheres. Desta forma, o CO ocupa a 
5º posição entre todos os tipos de cânceres em homens e 12º em mulheres. Novos 
casos prospectivos, para ambos os sexos e todas as idades, aumentarão de 
363.626 em 2020 para 450.870 em 2030 (Globocan, 2018). 
Aproximadamente 90%–95% dos cânceres orais são histologicamente 
carcinomas de células escamosas (CEC) e acometem principalmente lábio inferior, 
língua e soalho bucal. Diversos fatores têm sido descritos como de risco para o 
desenvolvimento de carcinomas de células escamosas oral (CCEO) e parecem agir 
conjuntamente principalmente aumentando a taxa de mutações nas células. 
Fatores exógenos relacionados ao estilo de vida, especialmente o consumo de 
tabaco e a sinergia tabaco e álcool, parecem ser particularmente importantes, 
assim como, em alguns casos, a exposição à luz solar para lábio e o hábito de 
mascar fumo como betel têm sido descritos como fatores associados em algumas 
áreas do globo (D'Souza e Addepalli 2018; Cohen et al. 2018; Andisheh-Tadbir et 
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al. 2010). Fatores intrínsecos como a desnutrição, condição sistêmica, idade, 
gênero, fator hereditário e genes oncogênicos são relatados (GALBIATTI et al. 
2013).  
O tratamento do carcinoma oral e de cabeça e pescoço envolve cirurgia, 
radiação e quimioterapia em diversas combinações dependendo do estágio e sítio 
primário. Aproximadamente 40% dos pacientes em estágios iniciais (I e II) são 
tratados apenas com cirurgia ou radiação. Para a maioria dos pacientes com 
estágios localmente avançados (estágio III e IV), o tratamento ressecável ou 
irressecável envolve quimioradioterapia, com ou sem indução e quimioterapia como 
terapia sequencial. A metástase é tratada com combinação quimioterápica ou 
agente único. O tratamento para recorrências locais/regionais depende do local da 
recorrência, carga tumoral e antecedentes terapêuticos e pode variar de 
reintervenção cirúrgica/radiação ou nova irradiação com quimioterapia ou somente  
quimioterapia. Todos estes tratamentos, de alguma forma causam algum tipo de 
morbidade imediata ou tardia (Marur et al. 2016). 
A cirurgia é utilizada apenas para tumores ressecáveis em que as 
margens tumorais possam ser bem definidas e a função possa ser preservada. A 
radioterapia é utilizada no tratamento de tumores localmente avançados, 
empregada como adjuvante da cirurgia ou concomitante à quimioterapia. As doses 
de radiação variam de 60 Gy a 70 Gy. Apesar da atual utilização de radioterapia 
com modulação de intensidade, as glândulas salivares, músculos constritores da 
faringe, e glândula tireoide são muitas vezes prejudicados, levando à xerostomia, 
disfagia, aspiração crônica e hipotireoidismo. A quimioterapia é utilizada como 
neoadjuvante e adjuvante da cirurgia e radioterapia. A alta dose de cisplatina 
continua sendo o padrão radiossensibilizador no tratamento do carcinoma oral, 
porém pequenos benefícios na sobrevida tem sido observados com a utilização 
também de fluorouracil e composto de docetaxel, assim como medicamentos 
alternativos para radiossensibilização dos anticorpos monoclonais de EGFR como 
cetuximab e panitumumab têm sido estudados (Marur et al. 2016; Vidal et al. 2017). 
Embora a detecção e o tratamento da maioria das neoplasias malignas 
tenham melhorado nas últimas décadas, a alta taxa de mortalidade do carcinoma 
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de células escamosas oral (CCEO) permaneceu inalterada (Warnakulasuriya, 
2009). Como resultado, 145.000 mortes atribuídas ao CCEO ocorrem por ano 
(Globocan, 2018). Esses dados demonstram que as estratégias de prevenção não 
são eficazes; o diagnóstico ainda é tardio e os tratamentos atuais têm efetividade 
limitada (Winn et al. 2015; Jansen et al. 2015). Cerca de apenas 30% a 50% dos 
pacientes portadores de CCEO estarão vivos após três anos, indicando uma taxa 
de sobrevida global baixa, consideravelmente menor do que outros tipos de câncer 
tais como colorretal, colo de útero e mama (Haddad, Shin 2008; Curado, Hashibe 
2009). Usualmente os pacientes com CCEO experienciam recorrência loco-regional 
ou metástases à distância (Scully, Bagan 2008; Curado, Hashibe 2009).  
O desenvolvimento do CCEO pode ser precedido por alterações no 
epitélio oral denominadas de desordens potencialmente malignas (DPM). Dentre 
elas, as leucoplasias, são as mais frequentemente observadas na prática clínica 
(Cabarcos et al, 2018). Em 1978, a Organização Mundial de Saúde definiu a 
leucoplasia como uma “placa branca que não pode ser caracterizada clinicamente 
ou histopatologicamente como qualquer outra condição” (Waal, 2014). Atualmente, 
é definida como uma placa predominantemente branca de risco questionável, 
excluindo outras doenças ou distúrbios conhecidos que não apresentam risco 
aumentado de câncer (Warnakulasuriya et al. 2007). Microscopicamente as 
leucoplasias podem apresentar alterações não displásicas (hiperceratose, 
acantose) ou diferentes graus de displasia epitelial (Villa and Sonis, 2018). O risco 
de malignização de uma leucoplasia é variável na literatura, estudos mostram que 
a taxa de transformação maligna para câncer invasivo de displasia ou carcinoma in 
situ pode variar de 5% a 36%. Hiperceratoses podem transformar-se em carcinoma 
invasivo em até 11% a 30% dos casos. Existem alguns parâmetros relatados que 
supostamente predizem a transformação. Esses parâmetros incluem câncer 
previamente diagnosticado na região da cabeça e pescoço, idade avançada, 
homens tabagistas, duração da leucoplasia, tipo clínico e tamanho da leucoplasia. 
As leucoplasias homogêneas têm menor risco de transformação em comparação 
com os casos não homogêneos assim como, leucoplasias maiores oferecem maior 
risco. Também podem predizer malignização, leucoplasias presentes em mulheres 
não tabagistas. A região anatômica também pode predizer a malignização sendo 
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que as lesões situadas em bordo de língua, ventre de língua, soalho de boca e 
palato mole tem maior probabilidade de apresentarem displasia. A prevalência de 
leucoplasia para todas as idades pode ser de 1%, mas é maior em adultos idosos. 
A proporção homem-mulher varia em diferentes partes do mundo e fumar é o fator 
etiológico mais comumente associado ao seu desenvolvimento (Waal, 2014; Villa 
and Sonis, 2018). Uma classificação de três níveis de displasia é tradicionalmente 
usada por patologistas; onde existe um distúrbio arquitetural limitado ao terço 
inferior do epitélio com atipia citológica, chamada de discreta. Há também um tipo 
que apresenta um distúrbio arquitetural que se estende até o terço médio do 
epitélio (moderada) e a displasia intensa apresenta distúrbio arquitetural em mais 
de dois terços de profundidade do epitélio com atipia celular (Dionne, et al 2015). A 
evolução das leucoplasias para o CCEO ainda não é bem compreendida e foram 
feitos poucos progressos no entendimento deste processo nas últimas décadas 
(Villa and Sonis, 2018).  
Um passo apontado como fundamental é identificar os fatores 
moleculares que impulsionam o início e a progressão do CCEO, pois esses fatores 
podem direcionar novas terapias (Villa and Sonis, 2018). Vários genes e proteínas 
emergem como potenciais marcadores de displasia e transformação maligna de 
leucoplasias. O gene p16 é apontado como um gene supressor tumoral do ciclo 
celular normal, e é associado com a imortalidade celular em câncer. Além disso, 
altos níveis de expressão suprabasal de p53 estão correlacionados com o risco de 
transformação. No entanto, a presença de p53 sozinha não pode ser considerada 
um determinante específico da transformação maligna e um relato recente sugere 
que a superexpressão do p53, no contexto da perda de proteína p16 e da 
superexpressão da proteína Ki-67, aumenta substancialmente o valor preditivo 
positivo. Além disso, o valor negativo preditivo desses marcadores individuais pode 
chegar a 100% de especificidade, indicando verdadeira utilidade clínica. A 
imortalidade celular associada à displasia oral, está associada à perda da 
expressão do receptor do ácido retinóico (RAR) -b e p16INK4a (Dionne et al. 2015). 
Atualmente existe uma vasta literatura relatando o papel dos fatores de 
crescimento e seus receptores na ativação das vias de sinalização intracelulares 
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envolvidas na regulação da diferenciação, sobrevivência, metabolismo, mobilidade 
e crescimento celular nos diferentes tipos de câncer.  Isto porque, a desregulação 
dos fatores de crescimento, de seus receptores e das diversas vias de sinalização 
por eles estimuladas é responsável pela aquisição do fenótipo maligno, da 
capacidade de invasão e metástase dos tumores malignos (Cohen et al. 2011; 
Alyasiri et al. 2012; Thomaz et al. 2016). Estes estudos são fundamentais para 
compreender a patogênese do câncer, identificação de marcadores biológicos de 
progressão tumoral e para o desenvolvimento de terapias alvo que atuem na 
regulação dessas vias.  
Existem estudos com terapia alvo para câncer de boca e de cabeça e 
pescoço direcionados para membrana celular, vias de sinalização, fatores de 
crescimento e seus receptores como EGFR, HER2 e HER3, MET, entre outros 
(Marur et al. 2016). 
Neste sentido, a via do Fator Neurotrófico Derivado do Cérebro (BDNF, 
do inglês Brain-derived Neurotrophic Factor) e seu receptor Trompomiosina 
Quinase B (TrkB) vem sendo bastante estudada em câncer de pâncreas, pulmão, 
colón, próstata, mama, bexiga, neuroblastoma, meduloblastoma, mieloma múltiplo, 
entre outros (Lai et al. 2010; Roesler et al. 2011; de Farias et al. 2012; Yin et al. 
2015; Thomaz et al.2016; Akil, Perraud et al. 2016).  
O BDNF é um membro da família das neurotrofinas que são fatores de 
crescimento que participam da diferenciação, proliferação e sobrevivência de 
células neurais e da neurogênese nos sistemas nervosos central e periférico. Esta 
proteína foi identificada e isolada pela primeira vez em 1982 por Barde et al. do 
cérebro de porco como um fator de sobrevivência para neurônios sensoriais 
embrionários de galinhas em cultura. As neurotrofinas medeiam seus efeitos 
interagindo com receptores de superfície celular específicos, que são divididos em 
duas classes de acordo com a afinidade de ligação para os fatores de crescimento. 
O receptor de NGF de baixa afinidade (p75N~FR) é capaz de ligar todas as 
neurotrofinas com afinidade semelhante, mas não serve como um receptor 
funcional para a transdução de sinal. Com o passar do tempo, demonstrou-se que 
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a família de receptores de proteína tirosina quinase trk (trkA, trkB e trkC), constitui 
o componente essencial dos receptores de alta afinidade(Yamamoto et al.1996). 
Desde 1991, foi identificado como um ligante para o receptor de tirosina 
quinase B (TrkB) (Barde et al. 1982; Roesler et al. 2011; Levi-Montalcini 1987). O 
principal ligante para o BDNF são os receptores de membrana celular 
trompomiosina quinase (Trk) (Schecterson, Bothwell, 2010; Akil, Perraud, et al., 
2016), em especial o TrkB. A ligação do receptor de BDNF no TrkB desencadeia a 
sua dimerização através de mudanças conformacionais e autofosforilação de 
resíduos de tirosina no ambiente intracelular (Liu, Chan, Ye, 2016). Em câncer, a 
estimulação da via de sinalização do BDNF/TrkB promove a ativação de moléculas 
de sinalização como Akt (Figura 1), STAT3, Src, ERK e MAPK resultando no 
aumento da proliferação celular, resistência a apoptose, invasão, metástase e 
resistência a quimioterapia.  Desta forma, o aumento da expressão de BDNF/TrkB 
tem sido associado com comportamento mais agressivo de diferentes tumores 
malignos e pior prognóstico, devido ao seu papel nos processos de angiogênese, 
invasão, metástase e a resistência à quimioterapia (Kupferman et al. 2010; Guo et 
al. 2011; Roesler et al. 2011; Fujikawa et al. 2012; Okamura et al. 2012; Sasahira et 
al. 2013; Jia et al. 2015; Kim et al. 2015). Alguns autores também relatam que, o 
TrkB é uma proteína transmembrânica e que é codificada pelo proto-oncogene Trk 
humano, o qual tem a capacidade para adquirir propriedades oncogênicas. Este 
proto-oncogene, através de um rearranjo cromossômico adquire a capacidade de 
oncogênese participando nos processos de transformações malignas. 
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Figura 1. Ilustração da via de sinalização BDNF/TrkB/PI3K/Akt/m-TOR. 
Fonte: Autores 
Em câncer de cabeça e pescoço, apesar de poucos estudos terem sido 
realizados, o BDNF/TrkB  aparece altamente expresso nas células tumorais (Zhu et 
al. 2007; Yilmaz et al. 2010; Jia et al. 2015),  além de ter demonstrado relação com 
pior prognóstico, aumento da angiogênese e linfangiogênese (Sasahira et al. 2013), 
e de participar do processo de transição epitelial mesenquimal (EMT), que é 
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considerado um processo biológico chave na invasão tumoral e metástase de 
tumores epiteliais (Jia et al. 2015).  
A modulação terapêutica da via BDNF/TrkB tem sido investigada com a 
utilização de moléculas de baixo peso antagonistas de TrkB ou com anticorpos 
monoclonais com ação no BDNF ou TrkB (Camoratto et al. 1997; Thiele et al. 2009; 
Yilmaz et al. 2010; Odate et al. 2013; Tanaka et al. 2014). Ensaio clínico de fase I 
utilizando inibidores de Trk já foram realizadas e ensaios de Fase II estão 
atualmente em curso (Norris et al. 2011; Minturn et al. 2011). No entanto, a 
compreensão do papel do BDNF/TrkB no câncer, em especial no CEC de cabeça e 
pescoço, assim como os efeitos do bloqueio farmacológico da sinalização 
BDNF/TrkB e sua ação nas diferentes vias de sinalização PI3k-Akt-mTOR precisam 
ser elucidadas. Assim como, não há estudos que avaliam o papel desta via durante 
todo o processo de carcinogênese bucal e sua relação com a evolução dos casos 
necessita ser melhor elucidada. Com o intuito de melhor esclarecer o papel da via 
BDNF/TrkB/Akt em câncer de boca, foi realizada uma revisão de literatura e uma 
avaliação da imunomarcação em amostras histopatológicas. 
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ABSTRACT 
Brain-derived  neurotrophic factor  (BDNF) is a member  of the  neurotrophin family 
of growth  factors  that  was first known  as responsible for sustain  the  growth,  
function, and  plasticity  of  neural  cells.  BDNF  exerts   its  effects   by  binding  to  
the  tyrosine kinase  receptor B (TrkB). The  BDNF/TrkB  axis  has  been   reported 
to  be  overexpressed in several  neurogenic and non-neurogenic  tumors.  Its higher 
expression was associated with  a poor  prognosis  to  patients affected by different 
human  malignancies, tumor  growth,  invasion,  and  metastasis; epithelial-
mesenchymal transition and resistance to  chemotherapy. BDNF/TrkB  represent 
promising  targets to  the  development of  novel  anticancer therapies. Some  
clinical trials  are  currently  evaluating the  efficacy  of Trk protein-target drugs  in 
different types  of solid tumors.  To date, few groups  have  evaluated the  
BDNF/TrkB  pathway in head  and  neck  malignancies. The aims of this  study  were  
to  review  the  literature concerning the  role of BDNF/ TrkB activation  in head  and  
neck  squamous cell carcinoma  and  malignant  salivary gland tumors  and to 
discuss  future  perspectives of BDNF/TrkB-target therapy. 
 
KEYWORDS 
adenoid  cystic carcinoma,  head  and neck cancer,  oral squamous cell carcinoma,  
salivary gland cancer,  signaling pathway 
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1 INTRODUCTION 
In the past years, the paradigm for cancer  therapy  evolved from conventional  
non-specific    treatments  to  highly  selective,   mechanism-based drugs.1  
Therefore,  the  identification of deregulated molecular  networks in different types  of  
tumors  became  a  primordial  goal  in  the   challenging   battle   to  beat   cancer.   
Among  these, growth  factor  signaling pathways, neurotrophins and  their  
receptors represent emerging  targets for the  development of novel  anticancer 
therapies.2 
Brain-derived   neurotrophic  factor   (BDNF)  is  a  growth   factor member  of 
a family of functionally  and  structurally  related  proteins called  neurotrophins that  
also  includes  nerve  growth  factor  (NGF), neurotrophin  3  (NT-3),  and  
neurotrophin 4/5  (NT-4/5).   BDNF  is expressed mainly involved  in the  
differentiation of neurons, responsible for sustain  the  growth  and  function  of 
neuronal  synapses,  proliferation,  plasticity,  and  survival  of  neural   adulthood  
cells  in  the central  and  peripheral   nervous   system.  This  protein   was  
identified and  isolated  for  the  first  time  in 1982  by Barde  et  al. from  the  pig 
brain as a survival factor  for embryonic  sensory  neurons of chickens in  culture.   
Since  1991,   it  was  identified   as  a  ligand  for  tyrosine receptor kinase B 
(TrkB).2-4 
Both  BDNF  and  TrkB are  expressed by  T and  B lymphocytes, platelets,   
macrophages,  vascular   endothelial  cells,  epidermal,   and other   non-neural 
cells.5   In  oral  cavity,  BDNF  is  necessary for  the development of the dental  
papilla/pulp - beginning of the dental innervation;   modulation   of   proliferation,    
and    differentiation   of epithelial  and  mesenchymal cells; formation  and  
maintenance of the sensory   apparatus of  the  tongue   (morphogenesis  of  the  
gustatory epithelium).  BDNF-derived  gustatory epithelium  is required  for  gustatory   
axons   to  correctly   locate   and  innervate  fungiform  papillae with  BDNF-
mediated target   being  restricted to  a  critical  period  of development.6 
Current research has shown that  BDNF/TrkB  pathway facilitates tumor  progression 
stimulating  invasion, metastasis, and angiogenesis. BDNF/TrkB  system   has  also  
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been   reported to  be  responsible  for chemoresistance, through Akt/PI-3K  and  
MAPK signaling pathways, in selected models  of cancer.  It has been  shown  to be 
overexpressed in various  cancer  types  like head  and  neck  squamous cell 
carcinoma (HNSCC), pancreas,  Wilms’  tumors,  lung, breast,  gastric, hepatocellu-
lar, and  also myelomas  and  lymphoid  cancers.  In addition,  in various types  of 
tumors  the  overexpression of these proteins was associated with  more  aggressive   
behavior   and  poor  prognosis.7-22   Our  group was  the  first  to  identify  and  
explore  the  role  of BDNF and  TrkB in colorectal  cancer 23,24  and  has  been  
evaluating  this pathway in other cancers such as acute leukemia,25 Ewing 
sarcoma,26 medulloblastoma,27,28 and breast  and gynecologic  cancer.29 
Brain-derived  neurotrophic  factor  and  its receptor represent promising  
targets for  the   development  of  novel  anticancer therapies.10,27,30 Several series of 
Trk inhibitors with excellent  in vitro therapeutic  potential  have  been   reported  and  
a  number   of  compounds   have  gone  into  the  clinic.30   Some  undergoing 
clinical trials are  evaluating  the  efficacy  of  Trk protein-target drugs  in  different 
types  of solid tumors.31,32  The most  favorable  results  concerning  Trk inhibitors    
were    observed   in   tumors    that    harbor    NTRK   gene fusions.31 Trk inhibitors 
Entrectinib  and LOXO-101, for example, demonstrated sustained clinical responses 
among patients with metastatic or unresectable solid tumors  with NTRK mutations.31 
To date,  few  groups  have  evaluated the  BDNF/TrkB  pathway in head  and  
neck  malignancies.  Therefore,   in this  study,  we  aimed  to review  the  literature 
concerning the  role of BDNF/TrkB activation  in these tumors,  as  well  as  to  
discuss  future   perspectives of  BDNF/ TrkB-target  therapy. 
 
2 BDNF / TrkB IN HEAD AND NECK SQUAMOUS CELL CARCINOMA 
Head   and   neck   cancer   comprises   a  group   of  malignancies   that 
involve the  lips, oral cavity, pharynx,  and  larynx, with  squamous cell carcinoma  
(HNSCC) representing the most prevalent microscopic subtype. More  than  half a 
million cases  of  HNSCC have  been  estimated  to  occur  in 2012  worldwide.33,34  
Over  the  past  few  decades, significant advances  have  been   achieved   in  our  
understanding  of HNSCC, nevertheless, no absolute gain was  achieved  in the  
survival rates,35  and in 2012,  approximately 325  000  deaths occurred due  to 
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HNSCC.33   Different   groups  have  explored  the  role  of  BDNF/TrkB pathway in 
HNSCC in the  last years. The findings are summarized  in Table 1 and  Figure 1. 
Figure 2 illustrates  the  BDNF immunostaining in head  and  neck  squamous cell 
carcinoma  as in the  most  prevalent salivary gland cancers  that  will be discussed 
later on. 
The  study  by  Zhu  et  al.36  represents the  earliest  evidence  that TrkB is 
overexpressed in HNSCC. This study  assessed TrkB levels in the  total  lysates  of 
23 HNSCC tissue  samples  and in 21 HNSCC cell lines. All samples  (tissue and 
cells) presented detectable levels of this protein while the normal oral mucosa was 
absolutely negative. No association between  BDNF  stimulus  and  HNSCC  cells 
invasiveness was  observed in  this  pioneer   report.36   Kupferman   and  colleagues 
published  three  important studies  that  demonstrated the  association between   
BDNF/TrkB    pathway   and   HNSCC   aggressive    behavior.15,17,21  Their initial 
results  demonstrated  increased expression of BDNF and  TrkB in HNSCC tissue  
samples  and  cell lines,15  corroborating  with  Zuh  et  al.36  Nevertheless, the  
outcomes concerning cell invasive  potential of Kupferman  et  al.15  diverged  from 
those  initially reported  in   2007.36    Cell  migration   and   invasive   capacity   were 
increased  following  BDNF  stimulus.15   This  disagreement might  be explained  by 
the  fact  that  Kupferman  et  al. analyzed  the  effect  of a BDNF  concentration  
gradient   in  high  TrkB-expressing   cell  lines. These   authors also   observed that   
BDNF/TrkB   activated STAT3, AKT, and MAPK as downstream signaling cascades.  
TrkB knockdown inhibited  HNSCC cell migration  and  invasion,  but  had  no  
impact  on cellular  growth   in  vitro.  This  finding  suggested that   this  pathway 
have   an   impact   in  the   epithelial-mesenchymal  transition  (EMT), which  was  
confirmed   by  the  spindle-like  morphology   observed  in TrkB-overexpressing 
cells accompanied by a decrease in N-cadherin and  Twist expression. TrkB 
downregulation abrogates tumor  growth in orthotopically injected  tongue  tumors  
and led to an increase  in E- cadherin  expression, evidencing  the  role  of  this  
pathway in  tumor growth   and  EMT  in  vivo.  Based   on  these promising  results,   
this group  developed two  following  studies   to  evaluate   the  association between 
the  BDNF/TrkB pathway and HNSCC progression and resistance to  cisplatin.17,21  
Ylmaz et  al. observed that  a small molecule inhibitor  of the  Trk receptor family 
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(AZ64) was  capable  to  sig- nificantly suppress cell proliferation and motility.17 
Cisplatin-based chemotherapy   is  currently   the   most   common adjuvant  
treatment offered  for  patients with  HNSCC. Nevertheless, the   clinical response is 
quite   unsatisfactory.  Loco-regional   failure rates  can  reach  65%  and  the  3-year  
survival rate  37%.37  Therefore, it  is  of  great   importance to  identify  molecular  
pathways  involved with  HNSCC  resistance to  cisplatin.  Cisplatin-resistant 
HNSCC  cell lines overexpress BDNF and TrkB, and the  pathway activation  
significantly impacts  the  cisplatin-IC50.17,21  Yet, the  dose-response curves to   
AZ64   were    similar   between   cisplatin-resistant  and   parental HNSCC  cell  
lines.17   The  mechanism   by  which  TrkB inhibition  can impact  cisplatin  
resistance is rather  associated to  oncogenic  signaling,  once   AZ64  was  able  to  
inhibit  STAT3 and  Src.17    
 
TABLE 1   Results from currently  available studies  that  investigated the  role of 
BDNF/TrkB in head  and neck squamous cell carcinoma 
 
 
Head  and  neck  squamous cell carcinoma 
 
Authors  (year) Methods Main findings 
Zhu et  al. (2007)36 HNSCC tissue  samples TrkB is overexpressed in HNSCC tissues  and cell lines compared to normal 
 and cell lines oral mucosa.  BNDF stimulus  was not  associated with cell invasion in vitro. 
Kupferman  et  al. (2010)15 HNSCC tissue  samples BDNF and TrkB are expressed in more  than  50% of human  HNSCC tumors. 
 and cell lines BDNF/TrkB activation  in vitro upregulates cell migration, invasion, and EMT 
  markers.  TrkB inhibition suppresses tumor  growth  of orthotopic HNSCC tumor. 
Ylmaz et  al. (2010)17 HNSCC tissue  samples, TrkB was identified  in 30% of tumor  samples  and in orthotopically implanted 
 cell lines, and orthotopic model HNSCC tumors.  TrkB inhibition suppressed cell proliferation  and migration 
  and sensitize  cells to cisplatin. 
Dud as et  al. (2011)38 OSCC cell line co-cultured OSCC-associated fibroblasts  produce BDNF, and TrkB receptor expression 
 with periodontal ligament  fibroblasts was increased in OSCC co-cultured with fibroblasts.  This interaction induced 
  EMT in OSCC cells. 
Lee et  al. (2012)21 HNSCC cell lines and mouse BDNF/TrkB activation  is associated with HNSCC resistance to cisplatin by 
 tumor  xenografts triggering  Akt-dependent signaling pathways and anti-apoptotic proteins. 
Sasahira  et  al. (2012)39 OSCC tissue  samples  and cell lines TrkB is associated with proliferation,  invasive capacity,  and VEGF expression 
  in vitro and angiogenesis, lymphangiogenesis, and poor  prognosis  in vivo. 
Chodroff  et  al. (2016)40 Orthotopic tongue  cancer  model BDNF was significantly upregulated and its inhibition, using ANA-12, reversed 
  pain-like behaviors  induced  by the  tumor. 
HNSCC, Head  and neck squamous cell carcinoma;  OSCC, Oral squamous cell carcinoma. 
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F I GU RE 1    Schematic  illustration  of the  main findings regarding  BDNF/TrkB 
pathway regulation  and function  in head  and neck squamous cell carcinoma 
 
Furthermore, BDNF stimulus  increased MDR1  (multidrug  resistance 1) 
levels  and anti-apoptotic  protein   (XiAP) levels,  associated with  a  decrease  in 
pro-apoptotic protein   levels  (Bmi) in  cisplatin-resistant HNSCC  cell lines. 
Interestingly,  TrkB knockdown reduced BDNF expression, suggesting  a possible  
autocrine activation  of the  pathway involved  with HNSCC resistance. 
Tumor-associated fibroblasts  appear  to  have  a role  in activation of 
BDNF/TrkB  pathway in HNSCC.38   This idea  is supported by the study  of Dudas 
et  al., in which periodontal ligament  fibroblasts  were co-cultured  with  oral  
squamous  cell  carcinoma   (OSCC) to  obtain tumor-associated fibroblasts.  Under  
co-culture conditions,  TrkB gene and   protein   expression  increased  significantly  
in  OSCC  cells  but remained  null in tumor-associated fibroblasts.  BDNF 
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expression,  by the  other  side,  was  considerably higher  in fibroblasts  compared 
to OSCC  cell, and  co-culture conditions   significantly  increased  BDNF expression 
in tumor-associated fibroblasts.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FI GU RE 2    Representative images of BDNF immunostaining in head  and 
neck squamous cell carcinoma,  adenoid  cystic carcinoma,  and 
mucoepidermoid carcinoma  (original magnification,  200x) 
 
 
The association between BDNF/TrkB activation and neovascularization   in  
HNSCC  was   also  previously   evaluated.  Sasahira   et  al., 2012,   demonstrated  
that    TrkB  knockdown  in   OSCC   cell   lines decreased vascular  endothelial 
growth  factor  (VEGF), VEGF-C, and VEGF-D levels, inhibited  growth  ability, by 
activating  caspase-3, and reduced the  invasive  capacity,  by a decrease in MMP-2  
and MMP-9 levels. TrkB expression in OSCC tissue  samples  was significantly 
correlated with microvessel density, lymphatic vessel density, and poor disease-free  
survival.  This  group  was  also  responsible  for  demonstrating  that  RUNX3 
regulates TrkB expression in OSCC cell lines.39 
A  recent  study   demonstrated  an  association between  BDNF/TrkB 
activation  and pain in an orthotopic tongue  cancer  model.40  Initially, the  authors 
performed a molecular  characterization of the  neuronal  responses through RT-
PCR array  for  several  genes  known  to be involved  in activation  of the  pain 
29 
 
 
pathway.  Among more  than  80 genes   evaluated,  BDNF  levels   presented  the   
highest   difference between the  control  group  and  the  group  with  orthotopic 
tongue cancer.  BDNF  signaling  inhibition,  using  the  TrkB antagonist ANA-12, 
reversed pain-like behaviors  produced by the  tumor.40 
 
3 BDNF / TrkB IN MALIGNANT SALIVARY GLAND TUMORS 
Salivary  gland  tumors   (SGT) are  a  rare  and  heterogeneous  group of   
neoplasms    responsible  for   3%-5%   of   head   and   neck   neoplasms.41,42   The  
main  treatment option   is  surgery,  leading  to  significant   morbidity   and   variable   
survival  rates.   Thus,  there   is  an urgent   need   to  better  understand the  
mechanisms   underlying  the invasive  behavior  of  these tumors  in order  to  
develop  novel  therapeutic   strategies.  Despite  the   emerging   interest  in   
BDNF/TrkB molecular   signaling  in  tumor   progression,  drugs   that   inhibit   this 
pathway,   its  role  and  therapeutic potential in malignant  SGT, have not  been  
thoroughly investigated. Three  studies   were  found  in literature involving  the  role  
of  BDNF/TrkB  pathway in these tumors as  demonstrated on  Table 2.  All of  them  
were  performed in  adenoid   cystic   carcinoma   (ACC) that   represents  the   most   
prevalente malignant  SGT.42   This tumor  exhibits  a  slow  growth  pattern, 
presence   of  perineural   invasion  (PNI), lymph  node   involvement,   distal 
metastasis,  and  an  aggressive   behavior.43,44   A prominent  hallmark of   ACC  is  
perineural  invasion   (PNI)  that   represents  cancer   cell invasion   in,  around,   
and   through  the   nerves.   It  is  a  key  factor responsible  for  the  incomplete 
surgical  resection. The  mechanisms involved  in  the  PNI  of  ACC need   to  be  
elucidated and  could  be modulated  by  BDNF/TrkB  axis  and  epithelial-
mesenchymal transition  (EMT) process.45,46 
Kovalski, Paulino (2002) were  the  first to study  the  expression of BDNF in 
29  cases  of primary  ACC of the  head  and  neck.  All cases exhibited  diffuse  and 
uniform  cytoplasmic  staining  for BDNF in both the  luminal and abluminal cells 
regardless  of perineural  spread  status or histologic  grade.  BDNF was not  
expressed by other  common  salivary gland tumors, including those  with similar 
histology, such as polymorphous low-grade  adenocarcinoma. For these authors,  
BDNF may  play  a causative  role  in its  predilection for  perineural  invasion and 
subsequent protracted clinical course.47 
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Recent   studies   indicate  that   BDNF/TrkB  play  a  pivotal  role  in the  in 
tumor  cell migration  and  invasion  via epithelial-mesenchymal transition  (EMT)-like 
changes,   such   as  E-cadherin   downregulation and  N-cadherin upregulation in 
some  tumors.  These characteristics are associated  with  tumor   aggressiveness45.  
In  this  approach,   Jia et  al. (2015)  verifies  the  expression of BDNF, TrkB, and  E-
cadherin (an EMT biomarker)  in 76  primary  adenoid   cystic  carcinoma  (ACC) 
specimens and 20 normal  salivary gland tissues.  The high expression of TrkB and 
the  low expression of E-cadherin  were  significantly correlated  with  the  poor  
prognosis  of  patients with  ACC. Additionally, the  biological role of the  BDNF/TrkB 
axis in the  EMT progression of ACC was  evaluated using  ACC cell line. The  
results  of  the  in vitro assays  demonstrated that  rhBDNF treatment significantly 
downregulated  E-cadherin  expression and  upregulated N-cadherin expression in 
SACC cells, which  was  accompanied by  the  phenotypic changes from  epithelial  
to  mesenchymal morphology  and  by increased motility. Additionally,  obstruction of  
TrkB by its  inhibitor,  k252a,  significantly hindered the  progression of ACC cells 
through EMT indicating that  these targets may be exploited  for clinical therapy.   
TABLE 2   Results from currently available studies that investigated the role 
of BDNF/TrkB in salivary gland cancer. 
 
Table 2. Results from currently available studies that investigated the role of BDNF/TrkB in 
salivary gland cancer. 
 
 Salivary gland tumors  
Authors  (year) Methods Main findings 
Kowalski and Paulino (2002)
47 HNACC tissue  samples All HNACCs exhibited  diffuse  and uniform  cytoplasmic  staining for BDNF protein 
  expression in both  the  luminal and abluminal cells. BDNF may play a causative  role 
  in its predilection for perineural  invasion. 
Jia et  al. (2015)
45 SACC cell lines and tissue Overexpression of TrkB and BDNF and downregulation of E-Cadherin  were  correlated 
 samples with the  invasion  and metastasis in SACC. High TrkB and low E-cadherin  expression 
  were  correlated with poor  prognosis  of patients with SACC. BDNF-mediated TrkB 
  activation  contributes to the  EMT progression and the  poor  prognosis  in SACC. 
Shan et  al. (2016)
46 Salivary adenoid  cystic BDNF and TrkB were  significantly overexpressed in SACC tissue  samples  with more 
 carcinoma  cell lines and staining intensity  around  the  peripheral  nerve  in the  SACC tissues. 
 tissue  samples Co-culture of Schwann  cells with SACC cells promote increase  in BDNF secretion, 
  increase  of TrkB expression, induce  modification  in cell morphology  accompanied 
  by conversion of EMT hallmarks (downregulation of E‑cadherin and upregulation 
of N‑cadherin and vimentin), and increase  cell motility. 
 
These  results demonstrated that  the  BDNF/TrkB  pathway mediated the  
EMT pro- gression  of ACC and emphasis  that  prevention of BDNF/TrkB signal- ing  
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should  prove  helpful  as  a  novel  strategy for  the  treatment  of SACC. 
Shan  et  al. (2016)  investigated the  relationship of Schwann  cells (SC) 
and EMT in ACC via the  BDNF/TrkB  axis. Mimicking the  cross- talk  between ACC 
cells  and  SCs  in  the  PNI  process,   the  authors observed that   the  co-cultured  
SCs  with  ACC cells  secreted  more BDNF. Also, co-culturing  significantly 
repressed the  expression of E- cadherin,  but  promoted the  expression of EMT 
markers  (N-cadherin and  vimentin)  in the  SACC-83 cells. These  effects  were  
significantly blocked  by  TrkB inhibitor  (K252a). In 187  tissue  samples  of  SACC, 
the  expression levels  of  TrkB and  S100A4  were  both  significantly associated 
with PNI, while E-cadherin  was significantly inversely associated with  PNI. These  
results  indicated  that  the  interaction of SCs and  SACC-83  cells  mediated the  
PNI process   by  inducing  the EMT  via  the   BDNF/TrkB  axis.  Targeting   the   
interaction between SACC cells  and  SCs  by  inhibition  of  BDNF/TrkB  signaling  
may  be potential strategy for anti-PNI therapy  in SACC.46 
 
4 FUTURES PERSPECTIVES 
Taken  the  evidences together,  BDNF/TrkB-target therapy   emerges as  a  
promising   alternative  to   treat   head   and   neck   malignancies. Either  TrkB 
antagonists, or  monoclonal  antibodies against  BDNF or TrkB, might increase  
disease  control  and  improve  survival rates.  The most  favorable  results  are  
usually  observed in patients that  harbor NTRK gene  fusions.31  Stransky  et  al., 
(2014)  in a study  that  evaluated  the  proportion of fusions  involving a kinase in 20 
types  of solid tumors,   identified   NTRK2  (TrkB) fusions   in  HNSCC.48    However, 
since  this  first  repost,   no  further   study  was  conducted  concerning this  subject   
and  the  prevalence  of  NTRK2 mutations in  head  and neck malignancies  
remains  somewhat obscure. 
Most  drugs, such as Entrectinib  and Cabozantinib,  are multitarget and  act  
on  all Trk receptors as well as other  pathways.  LOXO-101, by the  other  side, is 
considered a specific  drug  once  it inhibits  only TrkA, B, and  C.32  Hence,  the  
precise  contribution of TrkB inhibition to  the   clinical  response  improvement 
cannot   be  established  with these drugs.  This issue  can  be  overcome by  testing  
highly  specific drugs  to  TrkB. Cazorla  et  al., 2010,  developed a  highly potent and 
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selective  TrkB inhibitor,  cyclotraxin-B,  able  to  inhibit  the  two  active sites  of TrkB 
(p-Y816/PLCc  and p-Y515/Shc),  as well as downstream processes.49  The  same  
group  also identified  a low-molecular-weight TrkB  ligand,  ANA-12,  which   
selective   inhibited   processes  down- stream  of  TrkB without altering  TrkA and  
TrkC functions.50   These discoveries  expanded the  horizons  allowing the  effects  
of TrkB-specific inhibition  to be analyzed.  To date,  only pre-clinical studies  
evaluated  the  role of these drugs  were  conducted; however,  the  effects on 
HNSCC and salivary gland cancer  remains  utterly  unexplored. 
 
5 CONCLUSIONS 
Activation of BDNF/TrkB pathway in HNSCC and salivary gland cancer  leads  
to  a  more   aggressive   phenotype.  The  studies   reviewed herein  showed that  
this  pathway induces  HNSCC cells proliferation and  invasion,  stimulates  EMT  
and  angiogenesis,  and  is  associated with  increased cisplatin resistance. 
Regarding  ACC, the  studies demonstrated that  the  BDNF/TrkB  pathway is 
significantly  associated with perineural invasion, migration, induction of epithelial- 
mesenchymal  transition  (EMT), and   metastasis. Furthermore, the prognostic value 
of TrkB expression was proved  in both  HNSCC and ACC. The association of 
BDNF/TrkB  activation  and  other  important outcomes, by the  other  side, remains  
completely  obscure.  The association  of this  pathway and  cancer  stem-cell  
population,  recognized by their  role in tumor  resistance, was never  analyzed.  
Besides, the prevalence of NTRK2 mutations in HNSCC and salivary gland cancer 
must  be  further  explored  in new  studies  comprising  representative samples.   
Several   studies   analyzed   the   impact   of  TrkB  inhibition through protein   
knockdown.  Inhibitory  drugs  with  potential to  be further  transposed to clinical 
trials need  to be evaluated in vitro and in vivo in HNSCC and  ACC. At least,  the  
role  of BDNF/TrkB  pathway  in other  important salivary gland  cancers,  such  as 
mucoepidermoid  carcinoma  and  acinic cell carcinoma,  has  never  been  explored 
and deserves a thorough study. 
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2.2 Activation of BDNF/TrkB/Akt axis may be involved in the acquisition of the 
malignant phenotype in potentially malignant disorders and predicts poor 
prognosis of oral squamous cell carcinoma  
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Abstract  
To evaluate the expression of brain-derived neurotrophic factor (BDNF), its 
tyrosine kinase receptor B (TrkB) and two downstream targets of this pathway, Akt 
and ribosomal protein S6 (RPS6), in normal oral mucosa (NOM), leukoplakia (OL) 
and oral squamous cell carcinoma (OSCC), and correlate this expression with 
OSCC patients’ outcomes, cell senescence and “stemness” profile. Ten cases 
of NOM, 33 OL and 72 primary OSCC were included. Cases of OSCC were 
assembled in tissue micro arrays (TMAs). Immunohistochemical analysis for BDNF, 
TrkB, p-TrkB, p-Akt and p-RPS6 were performed in all cases. Cell senescence and 
stemness profile of OSCC were evaluated through p16 and BMI-1 
immunohistochemical expression, respectively. The slides were scanned into high-
resolution images and immunohistochemical expression was quantified through 
digital analysis. Cut-off values were determined to evaluate the association of each 
marker with clinco-pathologic features. OSCC presented increased expression of 
BDNF/TrkB/Akt pathway compared to NOM and OL. OSCC diagnosed in advanced 
clinical stages presented an up-regulation of BDNF and p-TrkB. Moreover, 
overexpression of BDNF and p-Akt were identified as predictors of poor disease-
specific survival, with hazard ratios of 2.83 and 2.19 respectively.  The increase in 
stemness profile was correlated with a decrease in p-TrkB and p-Akt expression. 
Taken together these data suggest that BDNF/TrkB/Akt pathway is involved in the 
acquisition of the malignant phenotype during oral carcinogenesis. Furthermore, the 
increased availability of BDNF influences OSCC prognosis presumably by activating 
downstream targets such as Akt. Patients with increased expression of these 
proteins were more likely to experience shorter survival time.  
 
Keywords: head and neck cancer, biomarker, predictive value, prognosis, 
immunohistochemistry. 
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Introduction 
 Oral cancer is the most common malignancy of the head and neck region 
and represents a global health problem with 354,860 cases estimated in 2018.1 
Prospective new cases, for both sexes and all ages, increased from 363,626 
worldwide in 2020 to 450,870 in 2030. 1 In Brazil, the National Cancer Institute José 
Alencar Gomes da Silva (INCA) estimated 11,200 new cases of oral cancer in men 
and 3,500 in women in Brazil in the year 2018 (biennium 2018-2019). In this way, it 
occupies the 5th position between all types of cancers in men and 12º in women. 
Approximately 90% of the oral malignancies are squamous cell carcinomas (SCC) 
and are associated with alcohol and tobacco consumption.2 While the detection and 
treatment of most malignancies has improved over the last several decades, high 
mortality rate of oral squamous cell carcinoma (OSCC) has remained unchanged.3 
As a result, 125,384 deaths attributed to OSCC occur per annum. 1 These data 
demonstrate that prevention strategies are not effective; the diagnosis is still late 
and current treatments have limited effectiveness.4,5 
Oral carcinogenesis is a multi-step process that involves genetic and 
epigenetic alterations resulting in oral mucosa modifications that culminate with 
cancer manifestation. A significant number of OSCC can be preceded by 
asymptomatic clinical lesions collectively referred as oral potentially malignant 
disorders (OPMDs), with oral leukoplakia (OL) being the most prevalent disorder.6,7 
These lesions are defined as “altered epithelium with an increased potential for 
progression to OSCC.7 Histopathological examination revealed that OPMDs could 
vary from non-dysplastic (epithelial hyperkeratosis, hyperplasia, acanthosis) to 
different degrees of dysplasia. However, the evolution from dysplasia to invasive 
carcinoma is not yet well understood.6-8 The understanding of mechanisms driving 
oral carcinogenesis and OSCC behavior is a key step to improving oral cancer 
outcomes and development of new candidates for targeted therapies.9 
There is now an extensive literature reporting the role of deregulation of 
growth factors and their receptors in the activation of intracellular signaling 
pathways involved in the acquisition of the malignant phenotype and tumor 
behavior.10-12 They are involved in several cell process such as differentiation, 
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survival, mobility and cell growth in different types of cancer. In this sense, the 
brain-derived neurotrophic factor (BDNF) pathway and tropomyosin-related kinase 
B receptor (TrkB) has been extensively studied in pancreatic, lung, colon, prostate, 
breast, bladder, neuroblastoma, medulloblastoma, multiple myeloma, among 
others.13-16 
BDNF is a member of the neurotrophins family that are growth factors that 
participate in the differentiation, proliferation and survival of neural cells and 
neurogenesis in the central and peripheral nervous systems. The major ligand for 
BDNF are the cell membrane receptors, especially TrkB.16,17 BDNF receptor binding 
in TrkB elicits its dimerization through conformational changes and 
autophosphorylation of tyrosine residues in the intracellular environment.18 In 
cancer, stimulation of the BDNF/TrkB signaling pathway promotes the activation of 
signaling molecules such as Akt, STAT3, Src, ERK and MAPK resulting in 
increased cell proliferation, resistance to apoptosis, invasion, metastasis and 
resistance to chemotherapy. Thus, increased BDNF/TrkB expression has been 
associated with more aggressive behavior of different malignant tumors and worse 
prognosis.14,19-25 
In a recent literature review, our group evidenced that the activation of the 
BDNF/TrkB pathway in squamous cell carcinoma of the head and neck and salivary 
gland cancer leads to a more aggressive phenotype and induces the proliferation, 
invasion of SCC cells. In addition, this signaling pathway promotes tumor related 
angiogenesis and increased resistance of neoplastic cells to cisplatin.26 The 
association of BDNF/TrkB signaling pathway activation in HNSCC with tumor 
aggressiveness has been described, however important aspects never before 
evaluated still need to be elucidated.26,27 The association of this pathway and the 
population of cancer stem cells, recognized for their role in tumor resistance, have 
never been analyzed. There are no studies evaluating the role of this pathway 
throughout the oral carcinogenesis process. Lastly, the capacity of these markers to 
predict OSCC prognosis still needs to be validated in different populations to 
confirm its real prognostic value. Thus, the aim of the present study was to evaluate 
the expression of BDNF/TrkB and two downstream targets of this pathway, Akt and 
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ribosomal protein S6 (RPS6) during oral carcinogenesis and correlate it with OSCC 
cell senescence, stemness profile and patient’s outcomes. 
 
Materials and methods 
This study was approved by the Ethics Committee on Human Research 
(approval No. 56334716.9.0000.5327). 
 
STUDY POPULATION 
A manual retrospective search was performed in the archives of the 
Pathology Laboratory at the Clinics Hospital of Porto Alegre - Brazil to identify cases 
of primary OSCC diagnosed between 1996 and 2010. A total of eighty-seven cases 
of primary oral squamous cell carcinoma (OSCC) were retrospectively collected and 
retrieved from the archives of the Head and Neck Department of the Clinics Hospital 
of Porto Alegre (Brazil). Clinical data were collected from patient's medical files and 
hospital records like age, sex, tumor location, tumor stage, tumor recurrence, follow-
up, survival time (time difference between treatment and either the date of death or 
last follow-up) and disease-free survival (time between treatment and the date of 
recurrence). 
 Twenty-four cases of oral leukoplakia (OL) were selected in the archives of 
Oral Pathology of the Federal University of Rio Grande do Sul. Additionally, ten 
cases of normal oral mucosa (NOM) obtained from mucocele specimens were 
retrieved in the Federal University of Rio Grande do Sul for comparison purposes.  
 
TISSUE MICROARRAY (TMA) CONSTRUCTION 
OSCC specimens that were retrospectively collected were arranged into 
tissue microarray (TMA) blocks for immunohistochemical analysis. TMA 
construction was performed as previously.28,29 Briefly three representative areas of 
the invasive front were elected in the H&E slides of each case using an objective 
marker (Nikon Corp, Tokyo, Japan). A manual tissue arrayer (Sakura Co, Japan) 
was used to cut the respective cylindrical cores (2.0mm in diameter each) after 
matching the marked slides over the original paraffin block. Three cores of normal 
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mucosa inserted in the left upper corner of each recipient block for orientation. To 
enable the interpretation of TMAs, a map indicating the exact position of each case 
was performed.  
 
IMMUNOHISTOCHEMISTRY 
Histological sections of NOM, OL and OSCC TMAs slides were subjected to 
immunohistochemical staining for BDNF, TrkB, phospho-TrkB (p-TrkB), phospho-
Akt (p-Akt), phospho-ribossomal protein S6 (p-RPS6). Furthermore, OSCC were 
also subjected to moloney murine leukemia virus insertion site 1 (BMI1) and p16 
immunohistochemical analysis. Briefly, blocks were sectioned (3 μm) and placed on 
silanized slides. The slides were subsequently deparaffinized in xylene and 
hydrated in descending grades of ethanol. Antigen retrieval was performed for 30 
min in a citrate buffer solution heated to 90oC in a water bath. The slides were then 
incubated with the primary antibodies: BDNF (1:750, EPR1292, Abcam), TrkB 
(1:1000, Polyclonal, Abcam), p-TrkB Y706 + Y070 (1:100, Polyclonal, Abcam), p-
Akt s473 (1:200, EP2109Y, Abcam), p-RPS6 S235 + S236 (1:200, Polyclonal, 
Abcam), BMI1 (1:200, Polyclonal, Abcam) and p16 (1:1500, 2DA12, Abcam). All 
slides were then exposed to avidin–biotin complex and horseradish peroxidase 
reagents (LSAB Kit; Dako Cytomation). The reactions were revealed with 
diaminobenzidine tetrahydrochloride (DAB; Novocastra, Newcastle, UK) and 
counterstained with Mayer’s hematoxylin. Negative controls were obtained through 
incubation with nonimmune serum instead of primary antibodies. Positive controls 
for BDNF, TrkB, p-TrkB, p-Akt, p-RPS6, BM1 and p16 were human brain tissue, 
cervical carcinoma, human pancreas tissue, and human brain tissue respectively. 
Only brown color regardless of the color intensity will be considered as positive 
marking. 
 
DIGITAL ANALYSIS 
The immunohistochemical slides were scanned into high-resolution images 
using the Aperio Scanscope CS Slide Scanner (Aperio Technologies Inc, Vista, 
CA). The digital images obtained in .svs format were visualized using the 
ImageScope software (Aperio Technologies Inc., Vista, CA). Digital images were 
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analyzed for cytoplasm immunomarking with PixelCount V9 (Aperio Technologies 
Inc, Vista, CA, USA) by using specific input parameters (hue value, 0.1; hue width, 
0.5; color saturation threshold, 4 e -002; and intensity threshold ranging from 0 to 
240), the percentage of positivity was calculated and classified in 3 categories 
according to their intensity range as weak (from 155-240), moderate (from 120 to 
155), and strong staining (from 0 to 120). For membrane immunomarking, the 
algorithm Membrane V9 (Aperio Technologies Inc, Vista, CA, USA) was used and 
the percentage of positivity was calculated using (3+) Percent Cells, (2+) Percent 
Cells, (1+) Percent Cells. The final score of each tumor was calculated as the sum 
of the percentage of each category multiplied by their intensity scores using the 
following formule: ([%weak × 1]+[%moderate×2]+[%strong×3]). The results always 
ranged from 100 to 300. The digital images were analyzed for nuclear 
immunomarking with Nuclear V9 (Aperio Technologies Inc, Vista, CA, USA), using 
Total Nuclei number and Percent Positive Nuclei. 
 
STATISTICAL ANALYSIS  
The clinical and immunohistochemical data were analyzed using SPSS 
software (IBM Corporation, Armonk, NY), version 18.0. Initially, a descriptive 
analysis of clinic-pathologic features was performed for OSCC and OL. The 
Kruskal-Wallis test was used to compare raw values between NOM, OL and OSCC 
and significant differences were then analyzed using Dunn’s post-hoc test adjusted 
for Bonferroni error correction. Receiver Operating Characteristic (ROC) curves was 
constructed to establish the best cut-off point using “alive or deceased due to 
OSCC” as main outcome. The cut-off point was determined as the value presenting 
the highest sensitivity along with a good specificity. The proteins expression was 
then dichotomized in high(high) and low(low) expression. Correlation between clinic-
pathological features and proteins expression was evaluated using the chi-square 
test or fisher’s exact test. Binary logistic regression was used to determine the odds 
ratio. The univariable Cox proportional hazard regression model was performed to 
evaluate the prognostic value of BDNF/TrkB pathway expression in patients’ 
disease-specific survival (DSS). This value was also evaluated using a multivariable 
model controlled for age, gender and clinical stage. Kaplan-Meier cumulative 
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disease-specific survival curves were generated and compared using the log-rank 
test. Spearman correlation test was used to determine the correlation of BDNF/TrkB 
pathway proteins expression with BMI1 (stemness profile) and p16 (senescence 
profile). For all tests, p≤0.05 was considered indicative of statistical significance. 
 
Results 
STUDY POPULATION  
Seventy-two cases of OSCC and 33 cases of OL were included in the 
present study. The clinic-demographic profile of OSCC and OL patients is 
presented in Tables 1 and 2, respectively.  
 
BDNF/TRKB/Akt SIGNALING PATHWAY IS MORE EXPRESSED IN OSCC 
THAN OL AND NOM 
We first sought to understand the patterns of expression of proteins related 
to BDNF/TrkB pathway in NOM, OL and OSCC. We observed that all evaluated 
specimens were positive for BDNF, TrkB, p-TrkB, p-Akt and p-S6, however some 
important differences were observed among NOM, OL and OSCC (Figure 1A). 
Digital analysis was performed to determine the score of expression in each case 
considering positive the brown cytoplasmic staining. The mean score of all markers 
for NOM, OL and OSCC is presented in Figure 1B. NOM and OL showed similar 
expression of BDNF, TrkB, p-Akt and p-S6. They differed only concerning p-TrkB 
expression. OL had a higher score compared to NOM. OSCC presented increased 
expression of BNDF, TrkB, p-TrkB and p-Akt compared to NOM. Moreover, the 
malignant cells also had increased expression compared to OL for BDNF, TrkB and 
p-Akt. Interestingly, p-RPS6 expression decreased in OSCC compared to NOM and 
OL. 
 
BDNF/TRKB/Akt PATHWAY IS MORE EXPRESSED IN ADVANCED OSCC 
CASES AND IS ASSOCIATED WITH POOR OUTCOMES  
To evaluate the association between clinical features and outcomes with 
BDNF, TrkB, p-TrkB, p-Akt and p-RPS6 expression, the variables were 
dichotomized as previously reported in the statistical analysis section. The cut-off 
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values used for BDNF, TrkB, p-TrkB, p-Akt and p-RPS6 were respectively 210, 195, 
125, 142 and 134. Based on these values the patients were divided in two groups: 
high and low expression. 
Figure 2 illustrates all the significant associations between proteins involved 
in BDNF/TrkB pathway with clinical features and outcomes. At the time of diagnosis 
patients with BDNFhigh expression presented a 2.62-fold higher chance of having 
nodal metastasis (Figure 2A). Additionally, patients diagnosed in advanced clinical 
stages (TNM III or IV) presented elevated expression of the growth factor 
(BDNFhigh) and its phosphorylated receptor (p-TrkBhigh). The odds ratios for these 
associations were 8.0 and 5.4 for BDNF and p-TrkB, respectively (Figures 2B and 
2C).  
During the follow-up period, patients with p-Akthigh expression presented 
2.72-fold higher chance of having recurrences compared to patients with p-Aktlow 
expression (Figure 2D). Concerning the survival of OSCC patients, we observed 
that both BDNF and p-Akt were associated with poor outcomes. A higher chance to 
decease during follow-up of 3.54 for BDNFhigh expression and 2.83 for p-Akthigh 
expression were identified (Figures 2E and 2F).  
 
BDNF AND p-AKT EXPRESSION ARE ASSOCIATED WITH OSCC DISEASE-
SPECIFIC SURVIVAL  
The next step was to identify the capacity of proteins involved in BDNF/TrkB 
pathway to predict the DSS. The hazard ratio and p values obtained from Cox 
Regression hazard regression model are presented in Table 3. In our analysis, 
BDNF and p-Akt were identified as biomarkers associated with survival in OSCC 
patients. Univariate analysis demonstrated that the chance to die due to the disease 
in each time point was 2.83-fold higher in patients with BDNFhigh expression 
compared to BDNFlow and 2.19-fold higher in patients with p-Akthigh expression 
compared to p-Aktlow. When the model was controlled for age, gender and clinical 
stage, the hazard ratio values slightly changed and the p value increased to 0.09 for 
BDNF analysis and 0.08 for p-Akt. 
A visual inspection of the survival curves (Figure 3) reveals the evident 
difference among patients with BDNFhigh and BDNFlow expression and among 
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patients with p-Akthigh and p-Aktlow. Moreover, despite no significant difference was 
encountered, a tendency of different survival pattern can also be observed between 
patients with p-TrkBhigh and p-TrkBlow expression. After 50 months of follow-up the 
curves tend to distance themselves, demonstrating that patients with p-TrkBhigh 
expression have higher chances of deceasing after this time point. The log-rank test 
revealed significant difference between the curves for BDNF and p-Akt markers, 
corroborating with the results from Cox regression. 
  
BDNF/TRKB/Akt PATHWAY INCREASE EXPRESSION CORRELATES WITH 
MODIFICATION IN THE STEMNESS PROFILE  
Immunohistochemical analysis of p16 and BMI1 were used to evaluate cell 
senescence and the stemness profile, respectively. No association was observed 
between p16 expression and the BDNF/TrkB pathway proteins (Figure 4A), 
indicating that this pathway appears to have no impact on cell senescence. On the 
other hand, BMI1 expression was significantly correlated with p-TrkB and p-Akt. An 
increase in both proteins resulted in the decrease of BMI1 evidenced by a negative 
correlation coefficient (Figure 4A) and descending curves in the scatter plot graphs 
(Figure 4B and 4C).  
  
Discussion 
BDNF/TrkB axis has been implicated in multiple biological processes 
including tumorigenesis and tumor behavior.12-16 The binding of BDNF to TrkB 
triggers promotes the activation of numerous signaling pathways including Akt, 
STAT3, Src, ERK and MAPK, which play important roles in malignant 
transformation, tumor progression, metastasis, angiogenesis, and therapy 
resistance.14,19-26 Although this pathway has been previously studied in OSCC26,27 
we identified some important gaps in the literature, which were addressed in the 
present study. Our results significantly expand the knowledge concerning the role of 
this pathway in oral cancer. We demonstrated that during oral carcinogenesis an 
increase in TrkB activation occur at an early stage, while the increase of BDNF, by 
the other side, is observed when epithelial cells already achieved the malignant 
phenotype. In addition, we identified for the first time the association of this pathway 
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with the stemness capacity of OSCC cells. Interestingly, there is an inverse 
correlation between the p-TrkB and p-Akt with the stemness profile of OSCC. 
Finally, we validate in our population the prognostic value of BDNF and p-Akt. Both 
proteins were capable of predicting a shorter survival time in OSCC. 
Modifications in the epithelial tissue during oral carcinogenesis have been 
studied to understand the mechanisms involved with cell signaling regulation, cell 
proliferation and acquisition of malignant phenotypes. Nevertheless, no specific 
molecular marker to predict malignant transformation of oral lesions is established 
in the literature. Overall, our results reveled that BDNF/TrkB/Akt pathway was found 
in the epithelial cells of the NOM, OL and OSCC samples. For the first time, we 
identified that OSCC exhibit higher levels of BDNF, TrkB and p-Akt compared to 
OL, demonstrating that this pathway is more active in the malignant neoplasm 
already established compared to the most prevalent OPMD. It can be presumed 
that BDNF/TrkB/Akt modifications are associated with the progression of oral 
carcinogenesis and acquisition of a malignant phenotype. Indeed, in vitro studies 
demonstrated that BDNF stimulus is capable of increasing the migratory and 
invasive capacity of OSCC cells and inducing epithelial-mesenchymal 
transition,20,27,30 which are key mechanisms involved with the capacity of epithelial 
cells to invade the connective tissue through basement membrane rupture. In the 
present study, the follow-up information on OL patients was not available, limiting 
our analysis of associations of these markers with clinical outcomes. We believe it is 
important to further evaluate if an increased expression of BDNF/TrkB/Akt is 
capable of predicting malignant transformation of OL during follow-up. Interestingly, 
p-RPS6 expression was down-regulated in OSCC compared to NOM and OL. P-
RPS6 and p-Akt proteins are downstream target of phosphatidylinositol 3-kinase 
mammalian target of rapamycin mTOR (PI3K-mTOR) pathway that is implicated in 
epithelial tumors development and progression.  mTORC1 activation results in 
RPS6 phosphorylation. The higher expression of RPS6 in NOM and OL suggest 
that it might be involved in mechanisms related to cell differentiation. Results from 
other studies by our group corroborate with this hypothesis. We observed the 
importance of mTORC1 activation in keratoacanthoma, a well-differentiated 
epithelial neoplasm, with reduced rates of proliferation and  invasion31 and in 
50 
 
 
epithelial cells during the late stages of skin wound healing, when terminal 
differentiation.32 By the other way, in OSCC we observed an overexpression of Akt 
at serine 473 (p-AktSer473), indicating the activation of mTOR2 that is more 
associated with malignant tumors based on activation of tumor cells migration and 
invasion. Therefore, we believe that Akt overexpression in oral cancer triggers 
mTORC2 activation rather then mTORC1. This specific activation has been 
previously demonstrated in oral cancer cells and has been associated with clinically 
advanced tumors33 and in vitro chemoresistance.34  
Growth factors are recognized as major regulators of tumor progression, 
controlling events such as cell proliferation, invasion, migration and drug-resistance. 
Many cancer cells also acquire the capacity to synthesize and release growth 
factors to which they are responsive, leading to constitutive pathway activation.35 
Up-regulated growth factors might represent promising therapeutic targets and their 
identification is therefore of paramount importance. In the present study, we 
demonstrated that BDNF is overexpressed in OSCC cells, suggesting that 
neoplastic cells have the capacity to produce this growth factor inducing an 
autocrine loop with TrkB activation. Dudas et al., (2011) have also demonstrated 
that OSCC-associated fibroblasts also secrete BDNF, indicating that paracrine 
stimulus also occurs in the tumor microenvironment.30 The persistent activation of 
BDNF/TrkB pathway may promote a more aggressive clinical behavior. In the 
present cohort, patients with BDNF high expression had an increased risk of 
presenting nodal metastasis at the diagnosis. Previous in vitro studies had already 
established a correlation between BDNF stimulus and increased migratory/invasive 
capacity of OSCC cells.20,27 Besides, TrkB expression has also been previously 
correlated with lymphovascular invasion and lymph vessel density in OSCC 
samples.23,27 Combined, these data demonstrate the importance of BDNF/TrkB axis 
in the establishment of OSSC nodal metastasis, which is recognized as a major 
indicator of poor prognosis.36-38 
Nodal metastasis and clinical stage usually are effective in predicting the 
overall survival of OSCC patients.36 However, patients diagnosed within the same 
clinical stage commonly present distinct behavior during follow-up. Therefore, 
biomarkers are continuously being investigated in order to distinguish molecular or 
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cellular signatures with a greater predictive value. Herein, we identified BDNF and 
Akt as biomarkers associated with patients outcomes in a cohort of 72 patients with 
primary OSCC. The higher expression of both proteins was capable of predicting a 
shorter survival time of OSCC patients in univariate analysis. In multivariate 
analysis the model was controlled for multiple important factors such as age, gender 
and clinical stage. In this analysis, the p value of these associations increased to 
0.09 and 0.08 for BDNF and p-Akt, respectively. Despite these values are not 
normally considered significant, we believe that the high hazard ratios observed for 
BDNF and p-Akt, 2.19 and 2.48 respectively, still have clinical relevance. They 
indicate that BDNF and Akt have value in predicting DSS in OSCC patients. Despite 
TrkB expression was not significantly associated with DSS in our analysis, survival 
curves demonstrated a trend of poor prognosis in patients with p-TrkBhigh 
expression. Our results corroborate with previous findings that demonstrated the 
predictive value of BDNF/TrkB/Akt axis in OSCC patients. Recently, Moriwaki et al. 
identified that up regulation of BDNF was capable to predict OSCC disease-free 
survival in a cohort of 44 patients. Interestingly, these authors also observed that 
higher TrkB expression was associated with an important but not significant trend of 
poor prognosis.27 Sasahira et al. detected a significant association of TrkB positive 
expression with disease-free survival in their study comprising 102 patients with 
OSCC. BDNF was not evaluated in this study23 and Akt was not evaluated in neither 
of these studies.23,27 Yet, other groups have also detected Akt as a prognostic 
marker in OSCC.39,40 These findings reveal that over-activation of axis leads to a 
more aggressive behavior and therefore represent a promising therapeutic target. 
The ideal model of cancer treatment has evolved from conventional non-
specific agents to selective mechanism-based drugs.41 This new paradigm of target 
therapy can achieve high levels of success specially if allied with precision 
medicine. The molecular heterogeneity that can be observed within a similar clinical 
cancer phenotype imposes this necessity. In precision medicine, genomic, 
proteomic, transcriptomic and metabolomic markers can be used to identify patients 
who are likely to benefit from a specific treatment.42 Our results demonstrated that 
patients with overexpression of BDNF had significantly lower survival rates. This 
subset of patients could benefit from drugs targeting the BDNF/TrkB axis by using 
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either TrkB antagonists or monoclonal antibodies against BDNF or TrkB. Currently 
several Trk-inhibitors are in clinical development and being tested in clinical 
trials,43,44 however most of drugs are multitarget and act on all Trk receptors as well 
as other pathways. Cazorla et al., developed a low-molecular-weight TrkB ligand, 
ANA-12, capable of inhibiting the downstream processes of TrkB without modifying 
TrkA and TrkC functions.45 The effect of this compound was recently evaluated in 
OSCC cell lines. Selective inhibition of TrkB blocked proliferation and migration of 
poorly differentiated OSCC cells and also suppressed the tumor growth in an 
orthotopic transplantation mouse model using these same cell lines.27 The effect of 
ANA-12 in other mechanisms involved with OSCC progression, such as cell cycle 
regulation, senescence and percentage of cancer stem cells, remain unexplored.   
In the present study we evaluated in OSCC the correlation of BDNF/TrkB/Akt 
axis activation with cell senescence and cancer stem cells (CSC), using p16 and 
BMI-1 markers for this purposes. The p16INK4A gene encodes the p16 protein, that is 
well known for its capacity to inhibit the kinase activities of the cyclin D-dependent 
kinases CDK4 and CDK6 and therefore decelerate cell progression from G1 to S 
phase, inducing cell senescence.46 No significant correlation was observed between 
BDNF/TrkB/Akt and p16 positive cells. This result suggests that activation of this 
pathway has no influence on triggering of cell senescence thought up-regulation of 
cyclin-dependent kinase inhibitor p16. BMI1 is a component of the polycomb 
repressive complex 1 recognized to have a significant role in the maintenance of 
normal and CSCs.47 CSCs represent a subset of cells within the tumor bulk that 
have stem cell-like proprieties, such as self-renewal and multipotency.48 They have 
a unique potential for tumor initiation and are the main responsible for tumor relapse 
after treatment.48 BMI1 acts as an epigenetic modifier protein enabling the 
maintenance of self-renewal capacity of CSCs. Thus, BMI1 is highly enriched in 
CSCs.47 Recently, Yin et al. (2015) demonstrated that BDNF stimulates the 
maintenance of CSC in breast cancer and inhibition of TrkB leads to ablation of this 
population of tumor cells preventing the recurrence of these tumors in animal 
model.49 Our study was the first to evaluate the association between BDNF/TrkB 
axis with a marker of stemness capacity in OSCC. Remarkbly, we observed an 
inverse association of TrkB and Akt with BMI1 expression. Tumors with higher TrkB 
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and Akt that were associated with poor outcomes showed lower BMI1 labeling.  
Nowadays, the CSC phenotype is considered as a transient state that depends of 
microenvironment and therapeutic pressures. In melanoma, CSC oscillates 
between quiescent and active states depending of PI3K/AKT signaling pathway.50 
Therefore, we believe that some factors such as BDNF, TrkB and Akt could modify 
CSC plasticity in oral cancer resulting in modification in BMI1 expression. In 
agreement with this theory, some authors observed higher BMI1 expression in the 
initially/well-differentiated HNSCCs and declined in poorly 
differentiated/progressed tumors.51,52 Also, some authors found a statistically 
significant correlation between lack of BMI-1 immunoexpression and poor prognosis 
of OSCC patients.52,53 The relationship between the BDNF/TrkB/Akt pathways 
with CSC plasticity need to be better evaluated in future studies. 
In conclusion, our data demonstrate that BDNF/TrkB/Akt signaling pathway is 
more expressed in OSCC compared to OL and NOM indicating that they are 
involved in the acquisition of the malignant phenotype during oral carcinogenesis. 
Furthermore, the increased availability of BDNF influences OSCC prognosis and 
shorter survival time presumably by activating downstream targets such as Akt. In 
addition, BDNF/TrkB/Akt pathway increased expression was correlates with 
modification in the stemness profile by decreasing BMI1 expression. This study 
supports that BDNF/TrkB is an attractive therapeutic target for OSCC. 
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Figures and Table Legends: 
 
Table 1. Clinico-demographic features of OSCC patients included in the 
present study (n=72). 
 
Table 2. Clinico-demographic features of OL patients included in the present 
study (n=33). 
 
Table 3. Association between proteins involved in BDNF/TrkB pathway and 
OSCC disease-specific survival estimated by univariate Cox regression hazard 
regression model and multivariate Cox regression hazard regression model 
controlled for age, gender and clinical stage.  
 
Figure 1. BDNF/TrkB pathway in NOM, OL and OSCC. (A) Representative 
images of BDNF, TrkB, p-TrkB, p-Akt and p-S6 in NOM, OL and OSCC. (B) Mean 
expression of BDNF, TrkB, p-TrkB, p-Akt and p-S6 in NOM, OL and OSCC. 
Different uppercase letters in columns denote significant difference (p<0,05, 
Kruskal-Wallis test followed by post-hoc Tukey test adjusted for Bonferroni error 
correction).  
 
Figure 2. Stacked bar graphs illustrating significant associations of proteins 
involved in BDNF/TrkB pathway with OSCC clinical features and outcomes. (A) 
Association between BDNF status and nodal status at diagnosis. (B) Association 
between p-TrkB status and TNM stage at diagnosis. (C) Association between BDNF 
status and TNM stage at diagnosis. (D) Association between p-Akt status and 
recurrence during follow-up. (D) Association between BDNF status and patients’ 
outcome during follow-up. (E) Association between p-Akt status and patients’ 
outcome during follow-up. Odds ratio (OR) and 95% confidence interval (CI) 
determined by binary logistic regression and p value determined by Fisher’s exact 
test. 
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Figure 3. Kaplan-Meier disease specific survival curves for OSCC patients. 
(A) Overall disease specific survival. (A) Disease specific survival according to 
BDNF status. (B) Disease specific survival according to TrkB status. (C) Disease 
specific survival according to p-TrkB status. (D) Disease specific survival according 
to p-Akt status. (D) Disease specific survival according to p-Akt status. Survival 
curves were compared using the log-rank test. 
 
Figure 4. BDNF/TrkB pathway correlation with cell senescence and 
“stemness” profile. (A) Spearman correlation coefficients’ between BDNF/TrkB 
pathway proteins and BMI1 (stem cell marker) and p16 (senescence marker). (B) 
Scatter-plot between p-TkrB and BMI-1. Note that an increase in p-TrkB is 
correlated with a decrease in BMI-1. (C) Scatter-plot between p-Akt and BMI1. Note 
that an increase in p-Akt is correlated with a decrease in BMI-1.  
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Table 1. Clinico-demographic features of OSCC patients included in the 
present study (n=72). 
OSCC patients  Frequency (%) N 
Gender 
   Male  
   Female 
 
90.3% 
9.7% 
 
65 
07 
Age (mean ± SD) 59.83 (±10.51)  
Tobacco user 
  Yes/former user 
  Never 
 
96.7% 
3.3% 
 
69 
03 
Packyears - only for smokers (mean ± SD) 44.92 (±24.73)  
Alcohol user 
  Yes/former user 
  Never 
 
76.3% 
23.7% 
 
55 
17 
Pain 
   Yes 
   No 
 
93.2% 
6.8% 
 
67 
05 
Clinical aspect 
   Ulcer 
   Others* 
 
91.9 
8.1 
 
66 
06 
Site 
   Tongue 
   Floor of the mouth 
   Palate 
   Gingiva 
 
75.0% 
11.1% 
8.3% 
5.6% 
 
54 
08 
06 
04 
TNM  
   I/II 
   III/IV 
 
13.8% 
86.2% 
 
10 
62 
Nodal metastasis  
   Yes 
   No 
 
59.7% 
40.3% 
 
43 
29 
Treatment  
   Surgery 
   Surgery + Radiotherapy 
   Others** 
 
26.8% 
53.5% 
19.7% 
 
19 
39 
14 
Recurrence 
   Yes 
   No 
 
39.7% 
60.3% 
 
29 
43 
Outcome 
   Alive 
   Deceased  
 
63.4% 
36.6% 
 
46 
26 
              * Macule, patch or nodule.  
** Radiotherapy, Chemotherapy, Surgery (14.1%); Chemotherapy + Surgery (1.4%); Radiotherapy + 
Chemotherapy (1.4%); Radiotherapy (2.8%) 
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Table 2. Clinico-demographic features of OL patients included in the present study 
(n=33). 
OL patients   Frequency (%) N 
Gender 
   Male  
   Female 
 
51.5% 
48.5% 
 
17 
16 
Age (mean ± SD) 59.83 (±10.51)  
Tobacco user 
  Yes/former user 
  Never 
 
72.7% 
27.3% 
 
24 
09 
Alcohol user 
  Yes/former user 
  Never 
 
27.3% 
72.7% 
 
09 
24 
Site 
   Tongue 
   Floor of the mouth 
   Palate 
   Gingiva 
   Buccal mucosa 
   Labial mucosa 
 
7.1% 
17.9% 
17.8% 
25.0% 
28.6% 
3.6% 
 
02 
06 
06 
08 
10 
01 
Outcome  
   No lesion  
   Lesion Stable  
   Malignant transformation 
   Unknown  
 
6.1% 
18.1% 
3.1% 
72.7% 
 
02 
06 
01 
24 
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Table 3. Association between proteins involved in BDNF/TrkB pathway and OSCC 
disease-specific survival estimated by univariate Cox regression hazard regression 
model and multivariate Cox regression hazard regression model controlled for age, 
gender and clinical stage.  
 
 
    
 
 
 
 
    HR – hazard ratio; CI – confidence interval.  
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Figure 1. BDNF/TrkB pathway in NOM, OL and OSCC. (A) Representative 
images of BDNF, TrkB, p-TrkB, p-Akt and p-S6 in NOM, OL and OSCC. (B) Mean 
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expression of BDNF, TrkB, p-TrkB, p-Akt and p-S6 in NOM, OL and OSCC. 
Different uppercase letters in columns denote significant difference (p<0,05, 
Kruskal-Wallis test followed by post-hoc Tukey test adjusted for Bonferroni error 
correction).  
 
 
Figure 2. Stacked bar graphs illustrating significant associations of proteins 
involved in BDNF/TrkB pathway with OSCC clinical features and outcomes. (A) 
Association between BDNF status and nodal status at diagnosis. (B) Association 
between p-TrkB status and TNM stage at diagnosis. (C) Association between BDNF 
66 
 
 
status and TNM stage at diagnosis. (D) Association between p-Akt status and 
recurrence during follow-up. (D) Association between BDNF status and patients’ 
outcome during follow-up. (E) Association between p-Akt status and patients’ 
outcome during follow-up. Odds ratio (OR) and 95% confidence interval (CI) 
determined by binary logistic regression and p value determined by Fisher’s exact 
test. 
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Figure 3. Kaplan-Meier disease specific survival curves for OSCC patients (months) 
(A) Overall disease specific survival. (A) Disease specific survival according to 
BDNF status. (B) Disease specific survival according to TrkB status. (C) Disease 
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specific survival according to p-TrkB status. (D) Disease specific survival according 
to p-Akt status. (D) Disease specific survival according to p-Akt status. Survival 
curves were compared using the log-rank test. 
 
 
Figure 4. BDNF/TrkB pathway correlation with cell senescence and “stemness” 
profile. (A) Spearman correlation coefficients’ between BDNF/TrkB pathway 
69 
 
 
proteins and BMI1 (stem cell marker) and p16 (senescence marker). (B) Scatter-
plot between p-TkrB and BMI-1. Note that an increase in p-TrkB is correlated with a 
decrease in BMI-1. (C) Scatter-plot between p-Akt and BMI1. Note that an increase 
in p-Akt is correlated with a decrease in BMI-1.  
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4 CONCLUSÃO 
 
A revisão da literatura encontrada, demonstrou que a via BDNF / TrkB induz 
a proliferação e invasão de células tumorais do carcinoma espinocelular oral e de 
cabeça e pescoço, estimula a transição epitélio-mesênquima (EMT) e a 
angiogênese e está associada ao aumento da resistência à cisplatina. Em relação 
aos tumores de glândulas salivares, os estudos demonstraram que a via 
BDNF/TrkB está significativamente associada à invasão perineural, migração, 
indução de transição epitélio-mesênquima e metástase. Além disso, o valor 
prognóstico da expressão de TrkB foi observado tanto no CEC de cabeça e 
pescoço como em alguns subtipos de neoplasias de glândulas salivares. 
Outros achados importantes obtidos nesta tese mostraram o papel da via  de 
sinalização BDNF / TrkB / Akt na carcinogênese oral tendo em vista o aumento da 
expressão desta via de sinalização no CCEO em comparação com leucoplasia e 
mucosa bucal normal indicando que eles estão envolvidos na aquisição do fenótipo 
maligno. Além disso, o aumento da disponibilidade de BDNF influenciou o 
prognóstico do CCEO e está associado à redução do tempo de sobrevida dos 
pacientes. Além disso, a expressão aumentada da via BDNF / TrkB / Akt foi 
correlacionada com a modificação no perfil de células tronco tumorais diminuindo a 
expressão de BMI 1 e correlacionada com mTORC2 observada pela baixa 
expressão de p-RPS6 em CCEO. Com estes resultados, pode-se considerar que a 
via BDNF / TrkB /Akt seja um importante alvo terapêutico de forma isolada ou  
potencializando a quimioterapia disponível, na busca de tratamento mais efetivo  
para CCEO. Assim sendo, novos estudos avaliando o efeito da inibição desta via 
em modelos de carcinogênese oral em animais e em CCEO se fazem necessários.  
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ANEXOS 
ANEXO 1  APROVAÇÃO COMITÊ DE ÉTICA EM PESQUISA 
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